Cover Image
市場調查報告書

華氏巨球蛋白血症 : 開發平台分析

Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213065
出版日期 內容資訊 英文 199 Pages
訂單完成後即時交付
價格
Back to Top
華氏巨球蛋白血症 : 開發平台分析 Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 199 Pages
簡介

所謂華氏巨球蛋白血症(WM),是指體內產生大量被稱作巨球蛋白的異常蛋白質之非何杰金氏淋巴瘤(NHL)的一種,風險因子有年齡,性別,家族病史,C型肝炎,特定的自體免疫疾病等。尤其乾燥症(修格蘭氏症候群)等風險特別高。治療方法有幹細胞移植,生物學的治療,化療,放射治療等。

本報告涵括全球華氏巨球蛋白血症治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及他們開發中的產品評估等,為您概述為以下內容。

目錄

簡介

  • 分析範圍

華氏巨球蛋白血症概要

治療藥的開發

  • 華氏巨球蛋白血症開發中產品:概要
  • 華氏巨球蛋白血症開發中產品:比較分析

華氏巨球蛋白血症:開發中的治療藥:各企業

華氏巨球蛋白血症:開發中的治療藥:大學·研究機關別

華氏巨球蛋白血症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

華氏巨球蛋白血症:開發中的產品:各企業

華氏巨球蛋白血症:開發中的產品:大學·研究機關別

華氏巨球蛋白血症:治療藥的開發企業

  • AbbVie Inc.
  • arGEN-X BV
  • Bayer AG
  • BeiGene(Beijing) Co.,Ltd
  • Calithera Biosciences, Inc.
  • Celgene Corporation
  • Genentech, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Idera Pharmaceuticals, Inc.
  • IGF Oncology, LLC.
  • Incyte Corporation
  • Karyopharm Therapeutics, Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Onyx Pharmaceuticals, Inc.

華氏巨球蛋白血症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (INCB-039110+INCB-040093)
  • 765IGF-MTX
  • acalabrutinib
  • ARGX-110
  • BGB-3111
  • kafiruzomibu
  • CB-839
  • copanlisib hydrochloride
  • DI-B4
  • entospletinib
  • Everolimus
  • FV-162
  • FV-214
  • HMPL-523
  • idelalisib
  • IMO-8400
  • INCB-39110
  • INCB-40093
  • INCB-50465
  • ixazomib citrate
  • lenalidomide
  • ofatsumumabu
  • oprozomib
  • pevonedistat hydrochloride
  • selinexor
  • 免疫學·腫瘤學 IRAK4 阻礙小分子
  • spebrutinib besylate
  • venetoclax
    • 產品概要
    • 作用機制
    • R&D的進展

華氏巨球蛋白血症:最近的開發平台趨勢

華氏巨球蛋白血症:暫停中的計劃

華氏巨球蛋白血症:開發中止的產品

華氏巨球蛋白血症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8527IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides an overview of the Waldenstrom Macroglobulinemia (Oncology) pipeline landscape.

Waldenstrom macroglobulinemia (WM) is a type of non-Hodgkin lymphoma (NHL) that produces large amounts of an abnormal protein (called a macroglobulin). Risk factors include age, gender, family history, Hepatitis C and certain types of autoimmune disease, such as Sjogren syndrome, might be at higher risk for WM. Treatment includes stem cell transplantation, biological therapy, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Waldenstrom Macroglobulinemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Waldenstrom Macroglobulinemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 16, 10, 1 and 3 respectively for Waldenstrom Macroglobulinemia.

Waldenstrom Macroglobulinemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Waldenstrom Macroglobulinemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Waldenstrom Macroglobulinemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Waldenstrom Macroglobulinemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Waldenstrom Macroglobulinemia Overview
  • Therapeutics Development
    • Pipeline Products for Waldenstrom Macroglobulinemia - Overview
  • Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies
  • Waldenstrom Macroglobulinemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Waldenstrom Macroglobulinemia - Products under Development by Companies
  • Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Amgen Inc.
    • arGEN-X BV
    • Aurigene Discovery Technologies Limited
    • Bayer AG
    • BeiGene, Ltd.
    • Calithera Biosciences, Inc.
    • Celgene Corporation
    • Genentech, Inc.
    • Gilead Sciences, Inc.
    • Hutchison MediPharma Limited
    • IGF Oncology, LLC.
    • Incyte Corporation
    • Juno Therapeutics Inc.
    • Karyopharm Therapeutics, Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Portola Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • Vivolux AB
  • Waldenstrom Macroglobulinemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dezapelisib + itacitinib adipate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 765IGF-MTX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acalabrutinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGB-3111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bortezomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CA-4948 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-839 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cerdulatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • copanlisib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dezapelisib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DI-B4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTRMWXHS-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • entospletinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMPL-523 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-50465 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itacitinib adipate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ixazomib citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCAR-015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • M-7583 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4059 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oprozomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selinexor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • spebrutinib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-659 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • venetoclax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VLX-1570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Waldenstrom Macroglobulinemia - Dormant Projects
  • Waldenstrom Macroglobulinemia - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Waldenstrom Macroglobulinemia - Dormant Projects, H2 2016
  • Waldenstrom Macroglobulinemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Waldenstrom Macroglobulinemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top